1. Generics Bulletin
  2. >>Products
  3. >>Generics

Sandoz: US Oral Solids And Injectables Have Reached Bottom

Novartis Unit Also Aiming To Move Up Value Chain As Standalone Business

 
• By Dean Rudge

Following Novartis’ announcement that it intended to spin-off its Sandoz business into a standalone company, management from both firms commented on several key issues facing Sandoz, including the US pricing and environment and arrangements for manufacturing.

Dollars (Helen Sessions/Alamy Stock Photo)
Are prospects in the US looking for up for generics manufacturers? • Source: Shutterstock (Alamy Stock Photo)

“The US generics oral solids and injectables business has now, we believe, reached a bottom, and with upcoming launches…can return to a growth profile,” Novartis AG CEO Vas Narasimhan has commented, a significant statement made for its Sandoz Inc. unit following significant pricing headwinds across the US generics sector in the last two years.

Narasimhan’s comments came as the originator disclosed plans to spin-off Sandoz into a standalone, publicly traded company, with an eye...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Three’s A Crowd? Celltrion Launches Denosumab In US

 
• By Dave Wallace

A third pair of Prolia and Xgeva rivals has now been launched in the US, with Celltrion throwing its hat into the ring after denosumab launches by Sandoz and Fresenius Kabi. But this is only the beginning for what is shaping up to be another highly competitive biosimilars market.

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By Dean Rudge

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Collating data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?